NCT03440346

Brief Summary

Attention deficit hyperactivity disorder (ADHD) is the most common childhood behavioural disorder, causing significant impediment to a child's development. The exact aetiology of ADHD is still unknown. It is a complex disorder with numerous contributing (epi)genetic and environmental factors. Currently, treatment predominantly consists of behavioural and pharmacological therapy. However, medication use is associated with several side effects and concerns about long-term effects and efficacy exist. Therefore, there is considerable interest in the development of alternative treatment options. Double-blind research investigating the effect of a few-foods diet (FFD) has demonstrated large improvements in ADHD symptoms. However, following an FFD requires great effort of both the child and parents. To make this treatment easier or potentially obsolete, it is important to understand how and in which children an FFD affects ADHD symptoms. The investigators hypothesise that an FFD affects brain function and behaviour, including ADHD symptoms, via the complex network of communication between the microbiota, gut and brain, i.e. the MGB axis. The aim of this study is to identify potential mechanism(s) underlying the impact of an FFD on ADHD symptoms and to identify biomarkers that predict the response to the FFD. 100 boys with ADHD will follow the FFD for 5 weeks. After inclusion, all participants will start with a baseline period, during which they will maintain their regular diet. The baseline period ends at the end of week 2. Thereafter, participants will follow a 5-week FFD, preceded by a 1-week transition period. The FFD period ends at the end of week 8. At the end of the baseline period (i.e. at the end of week 2) and at the end of the FFD (i.e. at the end of week 8), fMRI scans will be made, blood and buccal saliva will be collected, and stool and urine will be handed in. Children will do computer tasks and parents will complete questionnaires to monitor ADHD and physical complaints. All samples will be analysed by researchers blinded to behavioural responses to the FFD. To assess the impact of the FFD on brain function and the MGB axis, associations between ADHD behavioural changes and changes in other primary and secondary study outcomes will be analysed. This study may lead to the identification of biomarkers that can predict the response to an FFD. Understanding which changes - induced by an FFD - lead to improvements in ADHD symptoms may provide new avenues for developing treatments. Ultimately, the findings may enable personalised intervention strategies based on an individuals' configuration of the MGB axis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 19, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

February 19, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 22, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 21, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 21, 2019

Completed
Last Updated

July 1, 2019

Status Verified

June 1, 2019

Enrollment Period

1.3 years

First QC Date

January 19, 2018

Last Update Submit

June 28, 2019

Conditions

Keywords

Attention Deficit Hyperactivity DisorderADHDchildhumandietfew-foods dietbraingutmicrobiota

Outcome Measures

Primary Outcomes (4)

  • Change in neural activation patterns during execution of tasks

    Using fMRI, blood oxygen-level-dependent (BOLD) signal changes will be measured whilst performing cognitive tasks that assess inhibitory control and selective attention, i.e. a stop-signal task (response inhibition) and a Flanker task (response conflict and associated error monitoring). fMRI BOLD responses will be assessed between variable task-elements and performance. Region of interest (ROI; anatomically defined regions in the brain) analyses of the BOLD responses will be performed.

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

  • Change in peripheral blood metabolite concentrations

    Global metabolite profiles will be examined in plasma (or alternatively serum) obtained from whole blood using mass-spectrometry profiling. Phenylalanine and tyrosine plasma levels represent primary outcomes.

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

  • Change in functional composition of the gut microbiota

    Metagenome profiling will be performed on stool samples, leveraging Illumina next-generation sequencing technology. Sequence read data will be used for abundance profiling of microbiota genes that encode enzymes directly involved in the production or degradation of the dopamine and noradrenaline precursors phenylalanine and tyrosine.

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

  • Change in ADHD symptom scores

    ADHD symptoms will be scored using the 18-item ADHD rating scale, which is based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV and consists of 9 items that assess inattention and 9 items that focus on hyperactivity and impulsivity.

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

Secondary Outcomes (15)

  • Change in whole brain neural activation patterns during the execution of tasks

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

  • Change in whole brain functional connectivity at rest

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

  • Change in taxonomic and functional composition of the gut microbiota

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

  • Change in metabolite profiles

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

  • Change in peripheral blood cell gene expression profiles

    Before and at the end of the FFD intervention (i.e. at the end of week 2 and at the end of week 8)

  • +10 more secondary outcomes

Other Outcomes (2)

  • IQ-score

    At the screening session, prior to inclusion of participant in the study

  • Change in taxonomic and functional composition of the gut microbiota

    Prior to the screening (i.e. week 0) and after the baseline period (i.e. at the end of week 2)

Study Arms (1)

Few-foods diet intervention

EXPERIMENTAL
Other: Few-foods diet

Interventions

The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.

Also known as: Restricted Elimination Diet
Few-foods diet intervention

Eligibility Criteria

Age8 Years - 10 Years
Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Meeting DSM-IV ADHD criteria
  • Male
  • Aged 8 up to and including 10 years
  • Right-handed
  • Available to visit Wageningen University for 4 sessions (i.e. intake, screening, T1 and T2), of which 3 sessions including the child (screening, T1, T2)
  • Upon study start, fully understanding and agreeing to the study objectives and having dated and signed an informed consent to participate in the study, including permission that material will be used or archived for (epi)genetic testing
  • Willing to be informed about chance-findings that may have implications for the health of the child or his family, and approving of reporting this to the child's medical specialist or family's general physician.
  • If the child uses "over the counter" medication, e.g. laxatives, melatonin for sleeping problems or hay fever medication, parents are asked to share the information leaflet, and if necessary participants are asked to change to alternatives that are free of additives that may affect ADHD, e.g. laxatives free of artificial sweeteners, sugar and cacao.

You may not qualify if:

  • Diagnosis Autism Spectrum Disorder
  • Diagnosis Developmental Coordination Disorder
  • Premature birth (\< 36 weeks) and/or oxygen deprivation during birth
  • Diagnosed chronic gastrointestinal disorder, i.e. inflammatory bowel disease, irritable bowel syndrome, celiac disease, non-celiac gluten-intolerance (gluten-sensitivity) or lactose-intolerance
  • Auto-immune disorder (e.g. diabetes mellitus type 1)
  • Vegetarian/vegan
  • Diagnosis dyslexia and/or dyscalculia
  • IQ \< 85
  • Following behavioural therapy
  • Use of ADHD medication
  • Use of systemic antibiotics, antifungals, antivirals or antiparasitics in the past six months
  • Insufficient command of the Dutch language by either parents or child that may affect understanding and execution of study and dietary instructions
  • Family circumstances that may compromise following or completion of the diet, including but not limited to family relational problems
  • Having a contra-indication to MRI scanning (including, but not limited to): pacemakers and defibrillators, intraorbital or intraocular metallic fragments, ferromagnetic implants, claustrophobia.
  • Two weeks prior to the start of the study, dietary supplements (e.g. antioxidants, minerals, vitamins) or pro- or prebiotics use has to be stopped.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wageningen University

Wageningen, Netherlands

Location

Related Publications (3)

  • Pelsser LM, Frankena K, Toorman J, Savelkoul HF, Dubois AE, Pereira RR, Haagen TA, Rommelse NN, Buitelaar JK. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011 Feb 5;377(9764):494-503. doi: 10.1016/S0140-6736(10)62227-1.

    PMID: 21296237BACKGROUND
  • Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R. Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with ADHD. PLoS One. 2017 Jan 25;12(1):e0169277. doi: 10.1371/journal.pone.0169277. eCollection 2017.

    PMID: 28121994BACKGROUND
  • Stobernack T, de Vries SPW, Rodrigues Pereira R, Pelsser LM, Ter Braak CJF, Aarts E, van Baarlen P, Kleerebezem M, Frankena K, Hontelez S. Biomarker Research in ADHD: the Impact of Nutrition (BRAIN) - study protocol of an open-label trial to investigate the mechanisms underlying the effects of a few-foods diet on ADHD symptoms in children. BMJ Open. 2019 Nov 5;9(11):e029422. doi: 10.1136/bmjopen-2019-029422.

Related Links

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Study Officials

  • Michiel Kleerebezem, Prof. dr.

    Wageningen University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 19, 2018

First Posted

February 22, 2018

Study Start

February 19, 2018

Primary Completion

June 21, 2019

Study Completion

June 21, 2019

Last Updated

July 1, 2019

Record last verified: 2019-06

Data Sharing

IPD Sharing
Will not share

Locations